Email alerts

Subscribe to our mailing list

Testimonials

Since Tri-Solfen® was commercially launched, over 80 million lambs have been treated and over 80% of Australian wool growers are now using Tri-Solfen for their sheep. Here’s what some of them have to say…

‘We have used pain relief for two years now and seen real production gains. We are concerned for the welfare of our animals and will continue to use pain relief to ensure they get the best care.’

Clinton Wise– Wililoo Merino Stud, Woodanilling, W.A.

'It easy to see the difference pain relief makes. Before, lambs would walk away hunched up, even taking a couple of hours to walk back to the paddock. Now they run straight back to Mum and start suckling,” says Rod. “My wool is now sold under the Better Choices brand. I see this as a definite advantage. I think it will be an advantage in the long run, to both me and the industry as a whole.'

Rod Miller– Glenpaen Merino Stud, Horsham, Vic

'After being treated with pain relief my lambs were more content and less stressed. As farmers we are sincere in looking after the welfare of our animals and using pain relief demonstrates this.'

Richard Coole– Frankland, W.A.

'We have been using pain relief for the past three years. We’re impressed by reduced bleeding in the mulesing wound immediately after application. Lambs run straight back to find the ewe, which has dramatically reduced our mortality rates. Flock management, post lamb marking is easier due to the effect of pain relief and the scab healing faster.'

Ryan & Malcom O’Dea– Peepingee Merino Stud, Narrogin, W.A.

'Using pain relief eases the stress and allows lambs to mother up and move back to the paddock easier with faster weight gains.'

Kent Lummis– Waverley Downs, Gilgandra, NSW

Close

Patent Portfolio

Country Species Patent
Australia Sheep Granted
Australia Horses, Dogs, Lab animals Granted
Australia Cattle Granted
Australia Humans Granted
New
Zealand
Sheep,
Cattle
Granted
New
Zealand
Horses, Dogs, Lab animals Granted
EU Humans Granted
EU Pig, Sheep,
Cattle
Granted
USA Dogs, Horses, Lab animals Granted
USA Humans Granted
USA Pig, Sheep,
Cattle
Granted
Canada Horses, Dogs, Lab animals Granted
Canada Cattle,
Pig
Granted
Canada Humans Granted

Close

Advisory Board

Ian Page

Non-Executive Director

Ian is Chief Executive Officer of Dechra Pharmaceuticals, which has a 33% shareholder in Medical Ethics. He joined National Veterinary Services, Dechra’s former services business in 1989 and joined the Board of Dechra in 1997. In October 2010, Ian was appointed as Non-Executive Chairman of Sanford DeLand Asset Management.

Dr Chris Roberts

Human Wound and Regulatory Advisor

Chris has over 20 years’ line management experience of heading clinical research teams. He was previously global head of Smith & Nephew clinical support and market development, where he managed global clinical Phase II and III programmes in the management of venous and pressure ulcers.

Lieutenant Colonel Professor Steven Jeffery

Medical Specialist Advisor

Steve has over 15 years’ experience in military plastic surgery. In 2011 he was awarded the Military Civilian Partnership Award for ‘Regular of the Year’, as well as receiving the Wounds UK ‘Key Contribution’ award and the Smith and Nephew ‘Customer Pioneer of the Year’ award. He has also been awarded Fellowship of the Royal College of Surgeons of England ad eundum. He is an expert adviser to NICE Medical Technologies Evaluation Programme. Steve co-founded the Woundcare 4 Heroes charity, which is already making a big difference to the wound care of both serving and veteran personnel.

Dr Matthew Bayfield

Medical Specialist Scientific Director

Dr Matthew Bayfield, Head of Cardiothoracic Surgery, Strathfield Private Hospital and VMO Cardiothoracic Surgeon, Royal Prince Alfred Hospital.

Professor Peter Windsor

Veterinarian Research Advisor

Peter is a registered specialist veterinary surgeon in New South Wales and an emeritus Professor at Sydney University. He holds a BVSc (Hons), PhD, DVSc and diploma from the European College of Small Ruminant Health Management.

Dr Julian Braidwood

Global Regulatory Affairs Advisor

Julian has held leadership roles and managed international clinical projects with Grampian. He was previously Regulatory Affairs Manager at Novartis Animal Health. He is the Founder and Managing Director of Triveritas, where he is responsible for a team of 40 animal health specialists across the EU and the US.

Close

Press Release

Tri-Solfen registered in New Zealand for sheep and cattle husbandry procedures

November 16, 2017

Third registration received for the Group’s innovative pain mitigation product

Expanding Tri-Solfen’s commercial potential

Melbourne, Australia – 16 November 2017 – Medical Ethics Pty Ltd (“Medical Ethics” or “the Group”), a commercial and development company  focused on pain mitigation in wounds for humans  and animals, announces that its wholly owned subsidiary, Animal Ethics Pty Ltd (Animal Ethics), has successfully registered Tri-Solfen in New Zealand for sheep  and cattle husbandry procedures. Tri-Solfen is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improve wound healing. Tri-Solfen was registered through the Ministry for Primary Industries, which leads and facilitates the management of animal welfare policy and practice in New Zealand.

Over one billion livestock animals globally undergo highly invasive painful husbandry procedures annually. Tri-Solfen is already registered in Australia separately for sheep  and cattle husbandry procedures, where it is marketed and distributed by Bayer Animal Health, a global leader in animal health. To date, Tri-Solfen has been used to successfully treat over 80 million animals undergoing routine surgeries in the Australian livestock industries.

Animal Ethics accelerated the expansion of its global registration programmes earlier this year through a commercial partnership with Dechra Pharmaceuticals PLC (Dechra), a FTSE 250 international veterinary pharmaceutical business. As part of the partnership, Dechra became a cornerstone investor in Medical Ethics and, in a separate agreement with Animal Ethics, secured  the global licensing rights (excluding Australia and New Zealand) for the Group’s proprietary platform technology in animals. Dechra will support the Group’s strategy  to register Tri-Solfen in major international markets, such as the EU and US.

Allan Giffard, Managing Director of Medical Ethics, commented:

“Over one billion livestock animals globally undergo highly invasive painful husbandry procedures annually.  This registration is an important milestone for Medical Ethics as we further expand  our international reach and help to minimise suffering associated with wounds in livestock. Farming communities globally are responding to new animal welfare pressures,  and Tri-Solfen is proven to deliver a highly effective, practical and cost-efficient solution to improve animal welfare outcomes. We are currently in multiple marketing and distribution rights negotiations to bring this globally recognised technology to New Zealand.”

– Ends –

Contacts:

 

Medical Ethics Pty Ltd, Tel:  +61 419 362 286

Allan Giffard, Managing Director

Charles Olsson, Marketing Director

 

FTI Consulting, Tel: +44 20 3727 1000

Brett Pollard / Victoria Foster Mitchell / Abbas Omaar

 

Notes for editors:

About Medical Ethics Pty Ltd

Medical  Ethics  Pty Ltd  is a  commercial  and  development  company  focused  on  pain  mitigation  in  wounds  for humans  and  animals.  Our  vision  is to develop  and  deliver  our  proprietary  highly  effective,  safe, affordable  and practical pain relief platform to prevent  pain and  minimise suffering associated with wounds  in humans,  livestock and companion animals. Medical Ethics is focused  on the development of the Group’s patented technology initially for the treatment of chronic wounds such as diabetic leg ulcers. Animal Ethics, a wholly owned  subsidiary of Medical Ethics, is the first, and currently the only, company globally to develop, launch and commercialise a topical pain and wound management product for use in livestock undergoing painful husbandry procedures.

In March 2017, Medical Ethics secured  investment from Dechra Pharmaceuticals PLC (Dechra) in exchange for a 33% shareholding in the Group. A separate global license agreement (excluding Australia and  NZ) was entered into by Dechra  and  Animal  Ethics  to  secure  the  marketing  and  distribution  rights  of the Group’s  proprietary  platform technology in animals.

About Tri-Solfen

Tri-Solfen is a local anaesthetic and antiseptic gel spray that adheres well to wounds and acts as a barrier to environmental stimuli, promotes haemostasis and improves wound healing. Tri-Solfen contains two proven topical local anaesthetics; fast-acting Lignocaine for immediate pain relief and long-acting Bupivacaine for prolonged post- operative pain relief. Adrenaline is included for its ability to reduce  the shock and stress of blood loss, whilst prolonging the anaesthetic action. Tri-Solfen also contains Cetrimide; an antiseptic widely used to cleanse skin and wounds and provides protection from bacterial contamination.

The global market potential for Tri-Solfen is estimated to be in excess of AUD $350 million per year for the treatment of routine on farm procedures in calves, lambs and piglets.

Further information

Medical Ethics:

Allan Giffard, Managing Director
Charles Olsson, Marketing Director
+61 419 362 286

FTI Consulting:

Brett Pollard, Victoria Foster Mitchell
+44 (0)20 3727 1000